19 results on '"V.C. Di Maio"'
Number of results to display per page
Search Results
2. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen
- Author
-
Mario Starace, Valerio Giannelli, Nunzia Cuomo, Vanni Borghi, Aldo Bertoli, Anna Licata, Anna Claudia Pellicelli, C. Minichini, M. Andreoni, M. Di Stefano, Giuseppe Cariti, Enzo Boeri, Raffaele Cozzolongo, Roberto Gulminetti, E. Milano, Valeria Cento, Elisabetta Degasperi, Laura Sighinolfi, A. Raddi, Ivana Maida, Barbara Rossetti, Teresa Santantonio, Valeria Micheli, C. Masetti, P. Andreone, Giustino Parruti, F. Di Lorenzo, Ilaria Lenci, Tiziano Allice, Annapaola Callegaro, Elisa Biliotti, M. Lichtner, Teresa Pollicino, Pietro Lampertico, Gloria Taliani, Caterina Pasquazzi, Piero Colombatto, Alessia Giorgini, G. Raimondo, Antonio Craxì, Francesca Ceccherini-Silberstein, Filomena Morisco, Valeria Ghisetti, V.C. Di Maio, Giuliano Rizzardini, Silvia Galli, Stefania Paolucci, A. De Santis, A. Lleo, Vincenzo Sangiovanni, A. Ciancio, Maurizio Zazzi, Elisabetta Teti, Simona Marenco, William Gennari, Stefano Novati, Giovanni Cenderello, Simona Landonio, Manuela Merli, A. Scuteri, Nicola Coppola, C.F. Perno, Giulia Morsica, I. Beretta, Claudio Maria Mastroianni, Simona Francioso, Mario Angelico, Laura Ambra Nicolini, Chiara Dentone, Silvia Barbaliscia, G.B. Gaeta, Marianna Aragri, Ennio Polilli, L. Donnarumma, Vincenza Calvaruso, Bianca Bruzzone, Fausto Baldanti, V. Pace Palitti, Roberto Ganga, Maurizia Rossana Brunetto, C. Paternoster, Sergio Babudieri, M. Puoti, Hamid Hasson, and M. Rendina
- Subjects
medicine.medical_specialty ,Regimen ,Hepatology ,business.industry ,Internal medicine ,Gastroenterology ,medicine ,business ,NS5A - Published
- 2020
- Full Text
- View/download PDF
3. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance
- Author
-
M. Siciliano, Giulia Morsica, Anna Claudia Pellicelli, Silvia Galli, F. Ceccherini-Silberstein, Fausto Baldanti, Bianca Bruzzone, R. Campoli, Giuliano Rizzardini, Vincenza Calvaruso, Gloria Taliani, V. Pace Palitti, C. Masetti, P Paba, Antonio Craxì, Filomena Morisco, Ennio Polilli, V.C. Di Maio, Martina Milana, William Gennari, C.F. Perno, Rossana Scutari, Aldo Bertoli, Valeria Cento, M. Andreoni, V. Boccaccio, Marianna Aragri, G.B. Gaeta, M. Lichtner, Caterina Pasquazzi, Vanni Borghi, Laura Ambra Nicolini, Renato Maserati, G. Fiorentino, Sergio Babudieri, Elisabetta Degasperi, Giustino Parruti, Mario Angelico, L. Foroghi, Valeria Ghisetti, Silvia Barbaliscia, Carlo Magni, Valeria Micheli, Elisabetta Teti, Nicola Coppola, Stefania Paolucci, L. Sarmati, R. D’Ambrosio, Pietro Lampertico, M. Puoti, N. Iapadre, Stefano Bonora, and V. Guarneri
- Subjects
Natural resistance ,Oncology ,Focus (computing) ,medicine.medical_specialty ,Hepatology ,business.industry ,Internal medicine ,Treatment outcome ,Gastroenterology ,medicine ,Baseline (configuration management) ,DIRECT ACTING ANTIVIRALS ,business - Published
- 2019
- Full Text
- View/download PDF
4. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience
- Author
-
Pietro Lampertico, Valeria Cento, Claudio Maria Mastroianni, M. Puoti, Giuliano Rizzardini, Maurizio Zazzi, M. Lichtner, Bianca Bruzzone, Ivana Maida, Elisabetta Degasperi, C.F. Perno, M. Rendina, Giustino Parruti, Vincenza Calvaruso, Gloria Taliani, F. Di Lorenzo, Ilaria Lenci, Anna Claudia Pellicelli, Caterina Pasquazzi, Stefania Paolucci, A. Raddi, Marianna Aragri, Ennio Polilli, Giulia Morsica, Mario Starace, M. Andreoni, M. Di Stefano, C. Minichini, L. Donnarumma, V. Guarneri, Simona Marenco, Simona Landonio, Raffaele Cozzolongo, V. Pace Palitti, N. Cuomo, P. Andreone, Nicola Coppola, Silvia Galli, Mario Angelico, C. Paternoster, Roberto Ganga, Vanni Borghi, Elisabetta Teti, Sergio Babudieri, Silvia Barbaliscia, Anna Licata, Giovanni Cenderello, Antonio Craxì, Filomena Morisco, Maurizia Rossana Brunetto, V.C. Di Maio, Vincenzo Sangiovanni, A. Ciancio, Piero Colombatto, Valeria Micheli, Teresa Pollicino, Laura Ambra Nicolini, Alessia Giorgini, Valeria Ghisetti, S. Novati, Annapaola Callegaro, Aldo Bertoli, E. Milano, Roberto Gulminetti, A. De Santis, F. Ceccherini-Silberstein, Teresa Santantonio, C. Masetti, G. Raimondo, Di Maio, V.C., Aragri, M., Masetti, C., Paolucci, S., Bruzzone, B., Degasperi, E., Barbaliscia, S., Pollicino, T., Minichini, C., Calvaruso, V., Rendina, M., Cento, V., Teti, E., Micheli, V., Ghisetti, V., Polilli, E., Palitti, V. Pace, Landonio, S., Lenci, I., Donnarumma, L., Nicolini, L.A., Bertoli, A., Starace, M., Pasquazzi, C., Callegaro, A.P., Morisco, F., Cenderello, G., Marenco, S., Gulminetti, R., Novati, S., Guarneri, V., Andreone, P., Galli, S., Ciancio, A., Sangiovanni, V., Cuomo, N., Raddi, A., Morsica, G., Borghi, V., Maida, I., Brunetto, M., Colombatto, P., Cozzolongo, R., De Santis, A., Lichtner, M., Babudieri, S., Taliani, G., Santantonio, T., Di Stefano, M., Paternoster, C., Ganga, R., Puoti, M., Rizzardini, G., Pellicelli, A., Milano, E., Mastroianni, C., Licata, A., Di Lorenzo, F., Giorgini, A., Lampertico, P., Parruti, G., Coppola, N., Zazzi, M., Raimondo, G., Andreoni, M., Craxì, A., Angelico, M., Perno, C.F., and Ceccherini-Silberstein, F.
- Subjects
Resistance test ,medicine.medical_specialty ,Hepatology ,business.industry ,Gastroenterology ,DAA failur ,Vironet C ,NS5A ,Regimen ,Internal medicine ,medicine ,retreatment ,business - Abstract
Previous article in issueNext article in issue Introduction: There is a limited documentation about the retreatment of patients failing a recommended NS5A-containing regimen in Italy. Materials & methods: Within the VIRONET-C network, 386 NS5A-failing patients infected with different HCV-genotypes (GT) (GT1a/1b/2a-c/3a-b-g-h/4a-d-n-o-v=93/124/19/112/38) were analyzed. Retreatment of 105 failures was investigated. HCV-resistance-test was performed by Sanger-sequencing. Results: Failures following seven different NS5A-containing regimens were studied: 3D/2D (paritaprevir/ombitasvir ± dasabuvir) ± ribavirin (N = 72/4), daclatasvir/ledipasvir/velpatasvir + sofosbuvir ± ribavirin (N = 105/131/20), grazoprevir/elbasvir ± ribavirin (N = 34), glecaprevir/pibrentasvir (N = 20). Notably, 18.1% of NS5A-failing patients did not show any resistance-associated-substitutions (RAS), while 81.9% showed at least one NS5A-RAS, with multiclass-resistance in 35.5%. NS5A-RAS were observed more frequently in glecaprevir/pibrentasvir failures (GT1a 83.3%: Y93H + Q30H/D or +H58D; GT3a: 83.3% Y93H + A30K/G or +L31I) compared to sofosbuvir/velpatasvir (GT1a 16.6%: Y93H + Q30H, p = 0.08; GT3a 20.0%: Y93H/N + A30K/T, p = 0.03). To date, 105 failures have started a retreatment: sofosbuvir/velpatasvir ± ribavirin (N = 30), sofosbuvir/velpatasvir/voxilaprevir ± ribavirin (N = 67), glecaprevir/pibrentasvir (N = 4), grazoprevir/elbasvir ± sofosbuvir + ribavirin (N = 3), 3D + sofosbuvir + ribavirin (N = 1). The majority of patients were cirrhotic (51.9%) and relapsers (87.5%). The prevalence of NS5A-RASs before retreatment was 80.9%, with multiclass-resistance 29.5%. Among patients completing post-retreatment follow-up, a sustained-viral-response at week 12 (SVR12) was observed in 26/33 (78.8%). SVR4 was documented in 49/56 (87.5%). SVR12 was 76.0% with sofosbuvir/velpatasvir ± ribavirin (N = 25). Differently, SVR12 was 100% with glecaprevir/pibrentasvir for 8/12/16 weeks (N = 3), grazoprevir/elbasvir ± sofosbuvir + ribavirin for 12/24 weeks (N = 3) or 3D + sofosbuvir + ribavirin for 24 weeks (N = 1), despite the presence of NS5A-RASs. Until now, 67 patients started sofosbuvir/velpatasvir/voxilaprevir ± ribavirin recommended-retreatment for 12 weeks. 54/67 (80.6%) showed at least one baseline NS5A-RAS, 23/67 (34.3%) multiple-NS5A-RASs, and 22/67 (32.8%) multiclass-resistance. Of 25 patients with available outcome, 96.0% had SVR4. Only 1 GT1b infected patient was non-responder, without RASs before retreatment. Conclusions: In this real-life setting, NS5A-RASs were frequently detected at failure, and multiclass-resistance was around 30%. Overall, SVR after resistance-test-guided retreatment was >95%, with the exception of the sofosbuvir/velpatasvir retreatment. Our results show how HCV resistance-test at failure may be useful to optimize retreatment strategies.
- Published
- 2019
- Full Text
- View/download PDF
5. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life
- Author
-
L. Lambiase, Anna Claudia Pellicelli, Gloria Taliani, Barbara Menzaghi, Stefania Paolucci, Giuliano Rizzardini, Valeria Cento, Cesare Sarrecchia, Marianna Aragri, Francesca Ceccherini-Silberstein, M. Melis, M. Andreoni, Stefano Novati, Carlo Magni, Silvia Barbaliscia, Ilaria Lenci, V.C. Di Maio, Martina Milana, Elisabetta Teti, Mario Angelico, Caterina Pasquazzi, Aldo Bertoli, M. Puoti, A. Pecchioli, Valeria Micheli, Margherita Macera, Sergio Babudieri, Dante Romagnoli, Valeria Ghisetti, Laura Ambra Nicolini, Elisa Biliotti, Y. Troshina, Carlo Federico Perno, Fausto Baldanti, Simona Marenco, Nicola Coppola, T. Ruggiero, Manuele Koci Siciliano, Stefano Bonora, Alessia Ciancio, Cento, V, Barbaliscia, S, Lenci, I, Ruggiero, T, Magni, C, Paolucci, S, Babudieri, S, Siciliano, M, Pasquazzi, C, Ciancio, A, Perno, C, Ceccherini-Silberstein, F, Micheli, V, Troshina, Y, Biliotti, E, Milana, M, Melis, M, Teti, E, Lambiase, L, Menzaghi, B, Nicolini, L, Marenco, S, Di Maio, V, Aragri, M, Pecchioli, A, Bertoli, A, Sarrecchia, C, Macera, M, Coppola, N, Puoti, M, Romagnoli, D, Pellicelli, A, Bonora, S, Novati, S, Baldanti, F, Ghisetti, V, Andreoni, M, Taliani, G, Rizzardini, G, Angelico, M, Barbaliscia, I, and Ceccherini Silberstein, F
- Subjects
0301 basic medicine ,Male ,Cirrhosis ,Genotyping Techniques ,Sustained Virologic Response ,Hepacivirus ,Treatment failure ,chemistry.chemical_compound ,Liver disease ,0302 clinical medicine ,NS5A-inhibitors ,Genotypic resistance testing ,Treatment Failure ,Chronic ,HCV resistance ,biology ,Direct acting antivirals ,HCV failure ,Protease-inhibitors ,Retreatment ,Adult ,Aged ,Antiviral Agents ,Female ,Hepatitis C, Chronic ,Humans ,Microbial Sensitivity Tests ,Middle Aged ,Protease Inhibitors ,Sequence Analysis, DNA ,General Medicine ,Settore MED/07 - Microbiologia e Microbiologia Clinica ,Protease-inhibitor ,Hepatitis C ,humanities ,Infectious Diseases ,DIrect acting antivirals ,HCVFailure ,hcv-resistance ,030211 gastroenterology & hepatology ,Sequence Analysis ,Microbiology (medical) ,medicine.medical_specialty ,03 medical and health sciences ,Internal medicine ,medicine ,In real life ,Protease inhibitor (pharmacology) ,Cirrhosi ,business.industry ,Ribavirin ,DNA ,biology.organism_classification ,medicine.disease ,Surgery ,Regimen ,030104 developmental biology ,chemistry ,NS5A-inhibitor ,Direct acting antiviral ,business - Abstract
Objectives First-generation protease-inhibitors (PIs) have suboptimal efficacy in GT-1 patients with advanced liver disease, and patients experiencing treatment failure may require urgent retreatment. Our objective was to analyse the real-life efficacy of interferon (IFN)-free retreatment after PI-failure, and the role of genotypic-resistance-testing (GRT) in guiding retreatment choice. Methods In this multi-centre observational study, patients retreated with IFN-free regimens after first-generation PI-failure (telaprevir-boceprevir-simeprevir) were included. Sustained-virological-response (SVR) was evaluated at week 12 of follow-up. GRT was performed by population-sequencing. Results After PI-failure, 121 patients (cirrhotic = 86.8%) were retreated following three different strategies: A) with ‘GRT-guided’ regimens (N = 18); B) with ‘AASLD/EASL recommended, not GRT-guided’ regimens (N = 72); C) with ‘not recommended, not GRT-guided’ regimens (N = 31). Overall SVR rate was 91%, but all 18 patients treated with ‘GRT-guided’ regimens reached SVR (100%), despite heterogeneity in treatment duration, use of PI and ribavirin, versus 68/72 patients (94.4%) receiving ‘AASLD/EASL recommended, not GRT-guided’ regimens. SVR was strongly reduced (77.4%) among the 31 patients who received a ‘not recommended, not GRT-guided regimen’ (p
- Published
- 2017
6. VIROLOGICAL FAILURES TO NEW DIRECT ACTING ANTIVIRALS IN A REAL LIFE SETTING MAY REQUIRE UNCONVENTIONAL REGIMENS FOR RE-TREATMENT
- Author
-
Manuela Merli, M. Paoloni, Gabriella Verucchi, Simona Francioso, M. Melis, Vincenza Calvaruso, Caterina Pasquazzi, Marianna Aragri, F.P. Antonucci, Dante Romagnoli, Sergio Babudieri, G.B. Gaeta, M. Puoti, Ilaria Lenci, V. Pisani, Francesco Donato, Marco Biolato, Valeria Cento, D. Di Paolo, C.F. Perno, Mario Angelico, F. Ceccherini-Silberstein, Anna Claudia Pellicelli, Antonio Craxì, Filomena Morisco, V.C. Di Maio, Jacopo Vecchiet, Stefano Brillanti, Aldo Bertoli, Di Maio, VC, Cento, V, Di Paolo, D, Lenci, I, Aragri, M, Verucchi, G, Melis, M, Bertoli, A, Antonucci, FP, Francioso, S, Pellicelli, A, Calvaruso, V, Pasquazzi, C, Romagnoli, D, Biolato, M, Vecchiet, J, Morisco, F, Merli, M, Gaeta, GB, Brillanti, S, Donato, F, Puoti, M, Pisani, V, Paoloni, M, Babudieri, S, Craxi, A, Angelico, M, Perno, CF, and Ceccherini-Silberstein, F
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,DIRECT ACTING ANTIVIRALS ,Real life setting ,RAS, RAVS, RAV, HCV, DAA, THERAPY ,RAVS ,THERAPY ,RAS ,RAV ,HCV ,DAA ,03 medical and health sciences ,0302 clinical medicine ,medicine ,030211 gastroenterology & hepatology ,030212 general & internal medicine ,Intensive care medicine ,business - Published
- 2016
7. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies
- Author
-
Ilaria Lenci, A. Di Biagio, Giuliano Rizzardini, L. Marinaro, C. D'Ambrosio, Fausto Baldanti, Ivana Maida, G.B. Gaeta, M. Puoti, T. Ruggiero, Mario Angelico, Vincenza Calvaruso, Laura Sticchi, Mario Starace, Giustino Parruti, P. Cacciatore, Nicola Caporaso, Caterina Pasquazzi, Stefania Paolucci, Anna Claudia Pellicelli, M. Andreoni, C. Masetti, Sergio Babudieri, Gabriella d'Ettorre, Francesco Santopaolo, Raffaele Cozzolongo, P. Andreone, Carlo Magni, Valeria Cento, Guido Gubertini, J. Vecchiet, Stefano Novati, Nicola Coppola, C.F. Perno, Bianca Bruzzone, F. De Leonardis, V. Pace Palitti, Marianna Aragri, A. Grieco, Pierluigi Tarquini, G. De Stefano, G. Raimondo, Teresa Pollicino, Alessia Giorgini, Giorgio Barbarini, Valeria Ghisetti, G. Verucchi, M.C. Sorbo, Savino Bruno, M. Paoloni, F. Ceccherini-Silberstein, Roberto Gulminetti, Antonio Craxì, Filomena Morisco, Manuela Merli, V.C. Di Maio, Vincenzo Sangiovanni, A. Ciancio, Simona Francioso, Simona Landonio, Aldo Bertoli, A. Mancon, Valeria Micheli, Antonio Picciotto, V. Boccaccio, M. Melis, Ennio Polilli, F.P. Antonucci, Dante Romagnoli, and Silvia Barbaliscia
- Subjects
Oncology ,medicine.medical_specialty ,Hepatology ,business.industry ,Interferon free ,Gastroenterology ,DIRECT ACTING ANTIVIRALS ,03 medical and health sciences ,0302 clinical medicine ,Second line ,030220 oncology & carcinogenesis ,Internal medicine ,Medicine ,In real life ,030211 gastroenterology & hepatology ,business - Published
- 2017
- Full Text
- View/download PDF
8. The challenge of HCV-retreatment after DAA-failure: real-life experience advocates for caution
- Author
-
Vincenza Calvaruso, C. Masetti, Silvia Barbaliscia, Bianca Bruzzone, Giustino Parruti, Sergio Babudieri, Marco Biolato, Marianna Aragri, C.F. Perno, Vincenzo Messina, Valeria Cento, Simona Landonio, M. Melis, Carmine Minichini, Valeria Micheli, F. Ceccherini-Silberstein, Lucio Boglione, Giorgio Barbarini, Mario Angelico, Aldo Bertoli, Monica Schiavini, Laura Ambra Nicolini, Ennio Polilli, Raffaele Cozzolongo, Carlo Magni, Chiara Baiguera, C. Dentone, Giuliano Rizzardini, Anna Claudia Pellicelli, M. Siciliano, Y. Troshina, Antonio Craxì, Filomena Morisco, M. Puoti, V.C. Di Maio, A. Ciancio, Ilaria Lenci, Laura Sticchi, Stefania Paolucci, T. Ruggiero, Simona Marenco, and Nicola Coppola
- Subjects
0301 basic medicine ,03 medical and health sciences ,medicine.medical_specialty ,030104 developmental biology ,0302 clinical medicine ,Hepatology ,business.industry ,Immunology ,medicine ,030211 gastroenterology & hepatology ,Intensive care medicine ,business - Published
- 2017
- Full Text
- View/download PDF
9. Slow achievement of HCV-RNA undetectability in cirrhotic patients treated with sofosbuvir+ribavirin: possible clinical implications in the liver transplant list management
- Author
-
V.C. Di Maio, Francesca Ceccherini-Silberstein, Ilaria Lenci, Luciano Milanesi, Maria Chiara Colombo, M. Manuelli, Maria Francesca Donato, A. Castellaneta, Roberta Alfieri, M. Rendina, Martina Milana, Maria Laura Ponti, R. Canu, A. Di Leo, C.F. Perno, R. Ganga, Federica Malinverno, S. Monico, Mario Angelico, Valeria Cento, Daniele Sforza, Marianna Aragri, A. Abedrabbo, and Giuseppe Tisone
- Subjects
chemistry.chemical_compound ,medicine.medical_specialty ,Hepatology ,chemistry ,Sofosbuvir ,business.industry ,Ribavirin ,Internal medicine ,Gastroenterology ,medicine ,business ,medicine.drug - Abstract
Sofosbuvir (SOF) treatment ± ribavirin (RBV) prior to LT has the potential to change the HCV recurrence after Liver Transplantation (LT). This approach has been reported to avoid graft reinfection in compensated patients with hepatocellular carcinoma (HCC), but only among those who reached and maintained undetectable HCV-RNA (TND) before LT. Since the time to obtain this result in decompensated cirrhotics is unknown, we sought to investigate the early HCV-RNA decay in this setting. Sixteen decompensated patients (M/F 12/4, median age 55.3, CPT score>=B7), infected by HCV genotype 1a, 1b, 3 and 4 (2-8- 4-2), 4 of whom with HCC, were treated with SOF 400mg/day and RBV (200-1000 mg/day), except 2 who received SOF alone, for a median(IQR) of 12(11-16) weeks awaiting LT. HCV-RNA levels were measured weekly and safety and clinical parameters were analyzed. No serious adverse events were reported. The median(IQR) RBV dose was 600(400-800). Despite 11/16 patients had low baseline viremia (
- Published
- 2015
- Full Text
- View/download PDF
10. Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for re-treatment
- Author
-
Antonio Craxì, Filomena Morisco, M. Puoti, V.C. Di Maio, Nicola Caporaso, Anna Claudia Pellicelli, Francesca Ceccherini-Silberstein, M. Paoloni, Maria Stella Mura, G.B. Gaeta, F.P. Antonucci, Vincenza Calvaruso, R. Campoli, Gianluca Brancaccio, D. Di Paolo, Dante Romagnoli, Antonio Grieco, K. Yu La Rosa, Stefano Brillanti, Valeria Cento, Caterina Pasquazzi, Ilaria Lenci, Manuela Merli, Simona Francioso, M.C. Sorbo, M. Melis, Marco Biolato, C.F. Perno, Marianna Aragri, Aldo Bertoli, Gabriella Verucchi, Sergio Babudieri, V. Pisani, Mario Angelico, Francesca Donato, and J. Vecchiet
- Subjects
Oncology ,medicine.medical_specialty ,Hepatology ,business.industry ,Gastroenterology ,DIRECT ACTING ANTIVIRALS ,Virological failure ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,Medicine ,030211 gastroenterology & hepatology ,In patient ,business - Published
- 2016
- Full Text
- View/download PDF
11. Daclatasvir/sofosbuvir and ribavirin 800mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience
- Author
-
F. Ceccherini Silberstein, G. Cerasari, C.F. Perno, A. Moretti, L. Fondacaro, Giorgio Barbarini, F. Chiesara, Anna Claudia Pellicelli, R. Villani, C. D'Ambrosio, F.R. Ponziani, Sergio Babudieri, Maurizio Pompili, Rodolfo Sacco, Roberto Gulminetti, Pierluigi Tarquini, V. Pace Palitti, Vincenzo Messina, Antonio Izzi, V.C. Di Maio, F. Di Candilo, Valerio Giannelli, Vincenzo Iovinella, and Serena Dell'Isola
- Subjects
medicine.medical_specialty ,Hepatology ,Sofosbuvir ,business.industry ,Ribavirin ,Gastroenterology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,chemistry ,030220 oncology & carcinogenesis ,Internal medicine ,Genotype ,medicine ,030211 gastroenterology & hepatology ,business ,medicine.drug - Published
- 2017
- Full Text
- View/download PDF
12. The challenge of HCV-retreatment after DAA-failure: Italian real-life from VIRONET-C network
- Author
-
V. Cento, S. Barbaliscia, V.C. Di Maio, C. Masetti, C. Minichini, C.F. Magni, V. Micheli, S. Marenco, L.A. Nicolini, B. Bruzzone, Y. Troshina, C. Baiguera, C. Dentone, V. Calvaruso, S. Paolucci, M. Melis, M. Aragri, A. Bertoli, I. Lenci, S. Landonio, M. Schiavini, L. Sticchi, T. Ruggiero, E. Polilli, V. Messina, A. Pellicelli, L. Boglione, R. Cozzolongo, M. Biolato, F. Morisco, M. Siciliano, G. Parruti, G. Barbarini, A. Craxì, S. Babudieri, M. Puoti, A. Ciancio, G. Rizzardini, N. Coppola, M. Angelico, C.F. Perno, and F. Ceccherini-Silberstein
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Gastroenterology ,medicine ,Intensive care medicine ,business - Published
- 2017
- Full Text
- View/download PDF
13. P0915 : Clinical relevance of baseline/early detection and persistence of resistant associated variants in HCV-1 patients treated with protease-inhibitors assessed by ultra-deep sequencing
- Author
-
Francesca Ceccherini-Silberstein, Valeria Cento, Valeria Micheli, Antonio Picciotto, M. Santoro, Marianna Aragri, M. Andreoni, Ilaria Lenci, D. Di Paolo, Aldo Bertoli, Carlo Magni, Mario Angelico, M. Tontodonati, S. Bruno, Maria Concetta Bellocchi, Daniele Armenia, Cesare Sarrecchia, Maria Stella Mura, Gloria Taliani, Giuliano Rizzardini, F.P. Antonucci, Sergio Babudieri, F. De Leonardis, C.F. Perno, A. De Maria, A. Manunta, Giustino Parruti, Filomena Morisco, M. Puoti, V.C. Di Maio, J. Vecchiet, F. De Luca, Lorenzo Nosotti, Simona Francioso, Ennio Polilli, and L. Carioti
- Subjects
Oncology ,medicine.medical_specialty ,Protease ,Hepatology ,business.industry ,medicine.medical_treatment ,Early detection ,Ultra deep sequencing ,Bioinformatics ,Persistence (computer science) ,Internal medicine ,medicine ,Clinical significance ,business - Published
- 2015
- Full Text
- View/download PDF
14. P0903 : Slow HCV kinetics following sofosbuvir + ribavirin administration in real-life setting of liver transplant recipients with severe recurrent hepatitis C
- Author
-
C. Chialà, R. Canu, Maria Chiara Colombo, Giuseppe Tisone, Francesca Ceccherini-Silberstein, Fausto Zamboni, V.C. Di Maio, Antonio Picciotto, Luciano Milanesi, M. Manuelli, Giorgio Rossi, Ilaria Lenci, A. Di Leo, L. Mameli, M.C. Sorbo, M. Rendina, Daniele Sforza, Roberta Alfieri, Simona Marenco, A. Abedrabbo, Maria Francesca Donato, M.L. Ponti, Martina Milana, R. Ganga, Federica Malinverno, Valeria Cento, C.F. Perno, Marianna Aragri, S. Monico, and Mario Angelico
- Subjects
medicine.medical_specialty ,Hepatology ,Sofosbuvir ,business.industry ,Ribavirin ,Gastroenterology ,chemistry.chemical_compound ,chemistry ,Internal medicine ,medicine ,In real life ,Recurrent hepatitis ,business ,medicine.drug - Published
- 2015
- Full Text
- View/download PDF
15. T-09 Correlation between NS5A variants and fibrosis progression in patients with HCV recurrence after liver transplantation
- Author
-
G. Tisone, Ilaria Lenci, S. Cucchiarelli, D. Di Paolo, Mario Angelico, Valeria Cento, F.P. Antonucci, Martina Milana, F. Ceccherini Silberstein, V.C. Di Maio, Emiliano Giardina, F. De Luca, and C.F. Perno
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,medicine.medical_treatment ,Gastroenterology ,Hcv recurrence ,Liver transplantation ,medicine.disease ,Fibrosis ,Internal medicine ,medicine ,In patient ,business ,NS5A - Published
- 2013
- Full Text
- View/download PDF
16. OC-24 Genotype analysis, at baseline and early time-points, by population and ultra-deep sequencing in HCV patients treated with BOC/TVR-based therapy
- Author
-
Cesare Sarrecchia, L. Carioti, Valeria Cento, C.F. Perno, Daniele Armenia, M. Tontodonati, D. Di Paolo, Giustino Parruti, Sergio Babudieri, Maria Concetta Bellocchi, Mario Angelico, Giuliano Rizzardini, F. De Luca, F.P. Antonucci, F. Ceccherini Silberstein, V.C. Di Maio, and F. De Leonardis
- Subjects
Oncology ,medicine.medical_specialty ,education.field_of_study ,Hepatology ,business.industry ,Population ,Gastroenterology ,Genotype Analysis ,Ultra deep sequencing ,Bioinformatics ,Internal medicine ,medicine ,business ,education ,Baseline (configuration management) - Published
- 2013
- Full Text
- View/download PDF
17. 63 CORRELATION OF EARLY DETECTION OF HCV NS3-RESISTANCE AND VIROLOGICAL FAILURE IN PATIENTS TREATED WITH TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR
- Author
-
L. Carioti, C.F. Perno, Valeria Cento, Cesare Sarrecchia, V.C. Di Maio, Carlo Magni, D. Di Paolo, G. Madeddu, Sergio Babudieri, Francesca Ceccherini-Silberstein, Mario Angelico, F. De Leonardis, F.P. Antonucci, M. Tontodonati, Daniele Armenia, Giustino Parruti, Valeria Micheli, Giuliano Rizzardini, F. De Luca, and Maria Concetta Bellocchi
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Early detection ,University hospital ,Virological failure ,Telaprevir ,chemistry.chemical_compound ,Infectious disease clinic ,chemistry ,Boceprevir ,Internal medicine ,medicine ,In patient ,General hospital ,business ,medicine.drug - Abstract
63 CORRELATION OF EARLY DETECTION OF HCV NS3-RESISTANCE AND VIROLOGICAL FAILURE IN PATIENTS TREATED WITH TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR V. Cento, V.C. Di Maio, D. Di Paolo, F. De Luca, V. Micheli, M. Tontodonati, M.C. Bellocchi, L. Carioti, D. Armenia, F. De Leonardis, F.P. Antonucci, G. Madeddu, C. Magni, C. Sarrecchia, S. Babudieri, G. Parruti, M. Angelico, G. Rizzardini, C.F. Perno, F. Ceccherini-Silberstein. University of Rome Tor Vergata, University Hospital of Rome Tor Vergata, Roma, Hospital Sacco of Milan, Milan, Infectious Disease Clinic of Chieti, Chieti, University of Sassari, Sassari, Pescara General Hospital, Pescara, Italy E-mail: ceccherini@med.uniroma2.it
- Published
- 2013
- Full Text
- View/download PDF
18. 166 HCV DIVERSITY AND FIBROSIS PROGRESSION: NS5A AND CORE VARIANTS CORRELATE WITH SEVERITY OF HCV RECURRENCE AFTER LIVER TRANSPLANTATION
- Author
-
Ilaria Lenci, G. Tisone, S. Cucchiarelli, C.F. Perno, Martina Milana, D. Di Paolo, F.P. Antonucci, F. Ceccherini-Silberstein, V.C. Di Maio, Emiliano Giardina, Mario Angelico, F. De Luca, and Valeria Cento
- Subjects
Core (anatomy) ,medicine.medical_specialty ,Framingham Risk Score ,Hepatology ,business.industry ,medicine.medical_treatment ,Hcv recurrence ,Liver transplantation ,medicine.disease ,Virology ,Gastroenterology ,Obesity ,Fibrosis ,Internal medicine ,medicine ,Risk factor ,NS5A ,business - Abstract
Results: The overall 1-, 5and 10-year posttransplant survival rates, stratified by the composite risk score are presented in table 1. More than half (53.6%) of patients had at least one of the risk factors (obesity, renal dysfunction or advanced age). Patients with two or more risk factors (score ≥2) experienced a significantly higher covariate-adjusted risk of death compared to patients with zero (HR: 5.9, 95%CI: 2.3–14.3; p < 0.001) or one (HR: 2.6, 95%CI: 1.3–5.6; p = 0.009) risk factor.
- Published
- 2013
- Full Text
- View/download PDF
19. F-01 Baseline and early dynamic evaluation of HCV NS3-resistance
- Author
-
Cesare Sarrecchia, Mario Angelico, D. Di Paolo, C.F. Perno, F.P. Antonucci, Valeria Cento, M. Mapfumo, F. De Leonardis, Aldo Bertoli, F. De Luca, Ilaria Lenci, S. Cucchiarelli, V.C. Di Maio, F. Ceccherini Silberstein, Simona Francioso, Lorenzo Nosotti, and F. Antenucci
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Internal medicine ,Gastroenterology ,medicine ,Baseline (configuration management) ,business - Published
- 2013
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.